229 related articles for article (PubMed ID: 30983992)
1. Herbal Medicines for Irinotecan-Induced Diarrhea.
Tang L; Li X; Wan L; Xiao Y; Zeng X; Ding H
Front Pharmacol; 2019; 10():182. PubMed ID: 30983992
[TBL] [Abstract][Full Text] [Related]
2. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Barbounis V; Koumakis G; Vassilomanolakis M; Demiri M; Efremidis AP
Support Care Cancer; 2001 Jun; 9(4):258-60. PubMed ID: 11430421
[TBL] [Abstract][Full Text] [Related]
3. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Lenfers BH; Loeffler TM; Droege CM; Hausamen TU
Ann Oncol; 1999 Oct; 10(10):1251-3. PubMed ID: 10586346
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Abigerges D; Armand JP; Chabot GG; Da Costa L; Fadel E; Cote C; Hérait P; Gandia D
J Natl Cancer Inst; 1994 Mar; 86(6):446-9. PubMed ID: 8120919
[TBL] [Abstract][Full Text] [Related]
6. Novel agents that potentially inhibit irinotecan-induced diarrhea.
Yang X; Hu Z; Chan SY; Chan E; Goh BC; Duan W; Zhou S
Curr Med Chem; 2005; 12(11):1343-58. PubMed ID: 15975002
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Takagi T; Saotome T
Leuk Lymphoma; 2001 Aug; 42(4):577-86. PubMed ID: 11697485
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
Pro B; Lozano R; Ajani JA
Invest New Drugs; 2001; 19(4):341-3. PubMed ID: 11561696
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Michael M; Brittain M; Nagai J; Feld R; Hedley D; Oza A; Siu L; Moore MJ
J Clin Oncol; 2004 Nov; 22(21):4410-7. PubMed ID: 15514383
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
12. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.
Karthaus M; Ballo H; Abenhardt W; Steinmetz T; Geer T; Schimke J; Braumann D; Behrens R; Behringer D; Kindler M; Messmann H; Boeck HP; Greinwald R; Kleeberg U
Oncology; 2005; 68(4-6):326-32. PubMed ID: 16020959
[TBL] [Abstract][Full Text] [Related]
13. [Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)].
Sakata Y; Suzuki H; Kamataki T
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1241-4. PubMed ID: 8031168
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Ikuno N; Soda H; Watanabe M; Oka M
J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
[TBL] [Abstract][Full Text] [Related]
15. New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Alimonti A; Gelibter A; Pavese I; Satta F; Cognetti F; Ferretti G; Rasio D; Vecchione A; Di Palma M
Cancer Treat Rev; 2004 Oct; 30(6):555-62. PubMed ID: 15325035
[TBL] [Abstract][Full Text] [Related]
16. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
Int J Cancer; 2001 Apr; 92(2):269-75. PubMed ID: 11291056
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
18. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy-induced diarrhea].
Kobayashi K
Gan To Kagaku Ryoho; 2003 Jun; 30(6):765-71. PubMed ID: 12852342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
